Working… Menu

POETIG Trial - POnatinib After rEsisTance to Imatinib in GIST (POETIG)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03171389
Recruitment Status : Recruiting
First Posted : May 31, 2017
Last Update Posted : May 31, 2017
Hannover Medical School
Helios Klinikum Berlin-Buch
University Hospital Tuebingen
Universitätsmedizin Mannheim
University Hospital, Aachen
Helios Klinikum Bad Saarow
Information provided by (Responsible Party):
Sebastian Bauer, Universität Duisburg-Essen

No Study Results Posted on for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : September 22, 2018
Estimated Study Completion Date : September 22, 2020